We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CRP Tracking Predicts Potential Outcome for Hospitalized COVID-19 Patients

By LabMedica International staff writers
Posted on 16 Nov 2020
Print article
Image: Model of C-reactive protein (CRP) (Photo courtesy of Wikimedia Commons)
Image: Model of C-reactive protein (CRP) (Photo courtesy of Wikimedia Commons)
By tracking the increase in circulating levels of the inflammatory biomarker C-reactive protein, doctors are able to predict whether newly hospitalized COVID-19 patients will suffer respiratory deterioration with the possible need for intubation.

C-reactive protein (CRP) is a ring-shaped, pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. It is an acute-phase protein manufactured in the liver that increases following interleukin-6 (IL-6) secretion by macrophages and T-cells. Its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via C1q.

Investigators at Brigham and Women's Hospital (Boston, MA, USA) examined the theory that inflammatory biomarker levels could predict respiratory decline in patients who initially presented with stable disease. For this study, the investigators followed CRP levels in 100 COVID-19 patients admitted to the hospital.

Results revealed that a rapid rise in CRP levels during the first 48-to-72 hours of hospitalization was predictive of subsequent respiratory deterioration and intubation, while steadier CRP levels were observed in patients whose condition remained stable. Increasing CRP during the first 48 hours of hospitalization was a better predictor (with higher sensitivity) of respiratory decline than initial CRP levels.

"We realized that whereas a single CRP lab value from hospital admission was not very practical as a predictor of who might get sicker, tracking the rate of change from Day One to Day Two or Three was a very powerful and very clinically predictive test," said senior author Dr. Edy Yong Kim, instructor in medicine at Brigham and Women's Hospital. "Even though all of these patients looked clinically similar upon admission, as early as 24 hours after hospitalization, the immune systems of patients who would go on to the ICU multiple days later were already inflamed, as measured by these biomarkers. Because of our findings, we changed our guidelines at the Brigham to mandate CRP tracking every day for the first three days of hospitalization so that we could try to identify vulnerable patients and keep a close eye on their inflammation."

The CRP study was published in the October 28, 2020, online edition of the journal Cell Reports Medicine.

Related Links:
Brigham and Women's Hospital

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.